Related Experiment Videos
Evaluation of interferon treatment in cirrhotic patients with hepatitis C
1Second Department of Internal Medicine, Kurume University School of Medicine, Japan.
Insights
Interferon therapy shows benefits for selected cirrhotic hepatitis C patients, particularly those with lower pre-treatment virus levels and adequate platelet counts. Careful monitoring is essential due to potential adverse reactions like thrombocytopenia.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis.
- Interferon-based therapies have been used to treat chronic hepatitis C.
- The efficacy and safety of interferon in cirrhotic patients require further investigation.
Purpose of the Study:
- To evaluate the effects of interferon treatment on cirrhotic patients with hepatitis C.
- To assess the incidence of adverse reactions associated with interferon therapy in this population.
- To identify predictors of treatment response in cirrhotic hepatitis C patients.
Main Methods:
- A study involving 35 cirrhotic patients with hepatitis C and 29 chronic active hepatitis (CAH) patients without cirrhosis as controls.
- Interferon treatment regimens varied in dosage and duration between cirrhotic and CAH groups.
- Adverse events, treatment modifications, and treatment response (complete response) were monitored.
Main Results:
- Seven cirrhotic patients required treatment discontinuation or dose reduction, most commonly due to thrombocytopenia.
- Five cirrhotic patients (14.3%) and nine CAH patients (31.0%) achieved complete response.
- All complete responders with cirrhosis had pre-treatment hepatitis C virus RNA levels below 5 log copies/50 microliters.
Conclusions:
- Interferon demonstrates a beneficial effect in selected cirrhotic hepatitis C patients.
- Pre-treatment viral load and platelet count are important factors in predicting interferon response.
- Adverse reactions, especially thrombocytopenia, necessitate careful monitoring and potential dose adjustments.
Abstract:
The aim of this study was to examine the effects of interferon on cirrhotic patients with hepatitis C and the incidence of adverse reactions. The subjects were 35 cirrhotic patients, and 29 chronic active hepatitis patients without cirrhosis (CAH) served as controls. The cirrhotic patients received 3 or 6 million units of human lymphoblastoid interferon daily for one or two weeks and then three times a week for 22 or 23 weeks, while the CAH patients received 6 million units daily for 2 weeks and then three times a week for 14 or 16 weeks. Discontinuation of interferon treatment or dose reduction was required in the 7 cirrhotic patients. The most frequent reason was thrombocytopenia. Dose reduction alone was necessary in two CAH patients. Five cirrhotic patients (14.3%) and nine CAH patients (31.0%) were classified as complete responders to interferon treatment. In all five complete responders with cirrhosis, the hepatitis C virus RNA level before treatment was less than 5 log copies/50 microliters. The results of this study confirm the beneficial effect of interferon in selected patients with cirrhosis on basis of pre-treatment virus levels and platelet count.